SMN1 and proximal spinal muscular atrophy: Since higher SMN2 copy numbers are associated with reduced disease severity in SMA patients, most therapeutic efforts have focused on increasing expression of SMN through modulation of SMN2 splicing or SMN replacement by gene therapy [5–8].